Caring Brands (NASDAQ:CABR) Releases Earnings Results

Caring Brands (NASDAQ:CABR) issued its quarterly earnings data on Tuesday. The company reported ($0.27) EPS for the quarter, Zacks reports.

Caring Brands Trading Down 4.1%

NASDAQ CABR traded down $0.04 on Thursday, hitting $1.02. 51,638 shares of the stock traded hands, compared to its average volume of 122,947. The company has a 50-day moving average price of $1.04. Caring Brands has a twelve month low of $0.71 and a twelve month high of $5.35. The stock has a market capitalization of $9.09 million and a P/E ratio of -2.75. The company has a debt-to-equity ratio of 0.03, a current ratio of 13.16 and a quick ratio of 13.09.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings assumed coverage on Caring Brands in a research note on Monday, January 26th. They issued a “sell (e)” rating on the stock. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Caring Brands presently has a consensus rating of “Sell”.

Institutional Trading of Caring Brands

An institutional investor recently bought a new position in Caring Brands stock. Jane Street Group LLC acquired a new stake in shares of Caring Brands, Inc. (NASDAQ:CABR) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned approximately 0.25% of Caring Brands as of its most recent SEC filing.

Caring Brands Company Profile

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.